Abstract
Ischemia related diseases are on rise worldwide and have been shown to cause irreversible damage to the cells due to the blockage of blood supply to the tissue. Conventional therapies are less effective as they do not consider repair of the damaged tissues. Thus, alternative, stem cell-based therapies are currently under investigation. For example, hematopoietic stem cells (HSCs) were shown to give rise to vascular cells involved in neoangiogenesis; so, they have been tested in variety of animal models and small-scale clinical trials. Improvement in blood flow and tissue functionality was observed and adverse effects were not apparent. However, success of stem cell therapy is limited by the number of functional stem cells for clinical application. Numerous attempts are underway to address this issue via strategies that involve ex vivo expansion of stem cells preserving their stemness. This chapter outlines the mechanism of therapeutic angiogenesis, sources of HSCs, various methods of ex vivo expansion of HSCs via genetic regulators, cytokines and biomaterial scaffolds, and their preclinical and clinical applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggarwal R, Pompili VJ, Das H (2010) Genetic modification of ex-vivo expanded stem cells for clinical application. Front Biosci 15:854–871
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118:149–161
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Bagley J, Rosenzweig M, Marks DF, Pykett MJ (1999) Extended culture of multipotent hematopoietic progenitors without cytokine augmentation in a novel three-dimensional device. Exp Hematol 27:496–504
Blank U, Karlsson G, Karlsson S (2008) Signaling pathways governing stem-cell fate. Blood 111:492–503
Bryder D, Jacobsen SE (2000) Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. Blood 96:1748–1755
Chua KN, Chai C, Lee PC, Tang YN, Ramakrishna S, Leong KW, Mao HQ (2006) Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells. Biomaterials 27:6043–6051
Chua KN, Chai C, Lee PC, Ramakrishna S, Leong KW, Mao HQ (2007) Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells. Exp Hematol 35:771–781
Das H, Abdulhameed N, Joseph M, Sakthivel R, Mao HQ, Pompili VJ (2009a) Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. Cell Transplant 18:305–318
Das H, George JC, Joseph M, Das M, Abdulhameed N, Blitz A, Khan M, Sakthivel R, Mao HQ, Hoit BD, Kuppusamy P, Pompili VJ (2009b) Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One 4:e7325
Ding S, Wu TY, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG (2003) Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci USA 100:7632–7637
Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, Goldberg A, Hiatt HH, Glass J, Henshaw E (1971) Tumor angiogenesis – therapeutic implications. New Eng J Med 285:1182
Franke K, Pompe T, Bornhauser M, Werner C (2007) Engineered matrix coatings to modulate the adhesion of CD133+ human hematopoietic progenitor cells. Biomaterials 28:836–843
Gupta R, Tongers J, Losordo DW (2009) Human studies of angiogenic gene therapy. Circ Res 105:724–736
Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, Doan P, Chi JT, Salter AB, Lento WE, Reya T, Chao NJ, Chute JP (2010) Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med 16:475–482
Iruela-Arispe ML, Davis GE (2009) Cellular and molecular mechanisms of vascular lumen formation. Dev Cell 16:222–231
LaIuppa JA, McAdams TA, Papoutsakis ET, Miller WM (1996) Culture materials affect ex vivo expansion of hematopoietic progenitor cells. J Biomed Mater Res 36:347–359
Li Y, Ma T, Kniss DA, Yang ST, Lasky LC (2001) Human cord cell hematopoiesis in three-dimensional nonwoven fibrous matrices: in vitro simulation of the marrow microenvironment. J Hematother Stem Cell Res 10:355–368
Lin Y, Weisdorf DJ, Solovey A, Hebbel RP (2000) Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71–77
Losordo DW, Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109:2692–2697
Mohr JC, de Pablo JJ, Palecek SP (2006) 3-D microwell culture of human embryonic stem cells. Biomaterials 27:6032–6042
Mommaas B, Stegehuis-Kamp JA, van Halteren AG, Kester M, Enczmann J, Wernet P, Kogler G, Mutis T, Brand A, Goulmy E (2005) Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 105:1823–1827
Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, Taneera J, Fleischmann BK, Jacobsen SE (2004) Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10:494–501
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952–958
Rafii S, Lyden D (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9:702–712
Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM (2004) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44:1690–1699
Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111:150–156
Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361:45–46
Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP (2003) Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361:47–49
Wagers AJ, Sherwood RI, Christensen JL, Weissman IL (2002) Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297:2256–2259
Acknowledgements
This work was supported in part by National Institutes of Health grants, K01 AR054114 (NIAMS), SBIR R44 HL092706-01 (NHLBI), R21 CA143787 (NCI) and The Ohio State University start-up fund. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Lu, J., Aggarwal, R., Pompili, V.J., Das, H. (2012). Ex Vivo Expanded Hematopoietic Stem Cells for Ischemia. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 2. Stem Cells and Cancer Stem Cells, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2016-9_23
Download citation
DOI: https://doi.org/10.1007/978-94-007-2016-9_23
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2015-2
Online ISBN: 978-94-007-2016-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)